{"result": "(\"entity\"<|>UPTODATE INC.<|>ORGANIZATION<|>UpToDate Inc. is a medical resource providing clinical information and references for healthcare professionals.)\n##\n(\"entity\"<|>SNYDER PJ<|>PERSON<|>Snyder PJ is an author who contributed to the UpToDate references on hyperprolactinemia.)\n##\n(\"entity\"<|>HIPÓFISIS<|>GEO<|>The hypophysis, or pituitary gland, is an important gland in the endocrine system that regulates various hormones.)\n##\n(\"entity\"<|>SÍNDROME DE CUSHING<|>EVENT<|>Cushing's syndrome is a condition caused by excessive cortisol levels, often due to pituitary tumors.)\n##\n(\"relationship\"<|>SNYDER PJ<|>UPTODATE INC.<|>Snyder PJ authored clinical references published by UpToDate Inc.<|>7)\n##\n(\"relationship\"<|>HIPÓFISIS<|>SÍNDROME DE CUSHING<|>The hypophysis is involved in the development of Cushing's syndrome due to its role in hormone regulation.<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: a la                                       Todas las situaciones siguientes pueden aumentar los niveles de PRL excepto una:\n        prolactina por estímulo de estrógenos y progesterona (respuesta D).                                                               36\n        La macroprolactina se forma por la unión de la molécula nativa de PRL a la inmunoglobuli-                                             A. Traumatismo de pared torácica.\n        na G, aumentando su peso específico de 23 a 150-170 kDA. La presencia de macroprolac-                                                 B. Insuficiencia renal crónica.\n        tina causa hiperprolactinemia analítica, por disminución del aclaramiento de esta, pero no                                            C. Tratamiento con metoclopramida.\n        tiene relevancia clínica. Por tanto, ante la presencia de hiperprolactinemia analítica, pero                                          D.  Tratamiento con lisurida.\n        sin repercusión clínica, debe sospecharse esta entidad y excluirla para evitar tratamientos\n        innecesarios. El pretratamiento del suero con polietilenglicol hace precipitar los complejos\n        de macroprolactina y permite detectar la cifra real de PRL en el sobrenadante (respuesta B).                                          COMENTARIO\n        Referencias:                                                                                                                          El aumento de los niveles de PRL puede ser:\n        • Snyder PJ. Causes of hyperprolactinemia. En: Cooper DS, Martin KA, eds. UpToDate. Waltham, MA: UpToDate Inc.\n          https://www.uptodate.com (acceso 29 de abril de 2019).                                                                              •  Fisiológico: en situaciones como el embarazo, la lactancia, el coito, el sueño, ejercicio o el\n        • Snyder PJ. Clinical manifestations and evaluation of hyperprolactinemia. En: Cooper DS, Martin KA, eds. UpToDate. Waltham, MA:         estrés.\n          UpToDate Inc. https://www.uptodate.com (acceso 29 de abril de 2019).\n                                                                                                                                              •  Farmacológico: en relación             con fármacos        psiquiátricos (antipsicóticos,           antidepresivos,\n                                                                                                                                                 etc.), pero también otros como los antieméticos (metoclopramida) (respuesta C) (véase\n    35  ¿Cuál de estos fármacos es el que con mayor frecuencia produce                                                                           comentario de la pregunta 27).\n        hiperprolactinemia?                                                                                                                   •  Patológico: entre los que se incluirían el aumento de PRL por mecanismo neural, como en\n                                                                                                                                                 las lesiones de la pared torácica (respuesta A), o por disminución del aclaramiento como\n        A. Bupropión.                                                                                                                            en la enfermedad renal crónica (respuesta B) (v. tabla 3 en comentario de la pregunta 27).\n        B. Antagonistas del calcio.                                                                                                           Por el contrario, la lisurida es un agonista dopaminérgico que reduce los niveles de PRL\n        C. Venlafaxina                                                                                                                        y es una de las opciones en el tratamiento médico de la hiperprolactinemia junto con\n        D.  Risperidona.                                                                                                                      otros agonistas dopaminérgicos como la bromocriptina, la cabergolina o la quinagolida\n                                                                                                                                              (opción D falsa).\n        COMENTARIO                                                                                                                            Referencias:\n                                                                                                                                              • Villar-Taibo R, Sifontes-Dubon M, Bernabeu-Moron I, Casanueva FF. Prolactin excess and deficiency: Epidemiology, causes (excluding\n        Dentro de las causas farmacológicas de hiperprolactinemia, los antipsicóticos son la causa                                              prolactin-secreting pituitary tumors). En: Tritos NA, Klibansky A, eds. Prolatin disorders. From basic science to clinical management.\n                                                                                                                                                1.ª ed. Springer Nature Switzerland AG: Humana Press; 2019.\n        más habitual. Aunque son los antipsicóticos de primera generación los que causan más\n        elevación de PRL (en relación con un mayor bloqueo de los receptores D2 dopaminérgicos),\n        algunos de segunda generación, como la risperidona o la amisulpirida se asocian a frecuen-\n        tes y marcados aumentos de PRL (respuesta D).\n\n\n\n46                                                                                                                                                                                                                                                                           47\n---\n                                                                                                                                                                                                                                   HIPÓFISIS                        1\n\n\n\n    1.6 Síndrome de Cushing                                                                                                                  38  Una vez diagnosticado un paciente de hipercortisolismo, uno de los siguientes\n                                                                                                                                                 resultados de laboratorio no habla a favor de una enfermedad de Cushing:\n             Con respecto a los tumores hipofisarios causantes de síndrome de Cushing, señale                                                    A. ACTH elevada.\n       37                                                                                                                                        B. Frena con 8 mg de dexametaxona.\n             la respuesta correcta:                                                                                                              C. Test de desmopresina positivo.\n             A. La RMN es menos sensible que la TAC para detectar adenomas productores de ACTH.                                                  D.  No frena con 8 mg de dexametaxona.\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}